Veracyte, Inc. (VCYT) AI Stock Analysis

Veracyte, Inc. operates globally as a diagnostics company specializing in molecular diagnostic tests for cancer and pulmonary diseases. Its flagship tests include the Afirma Genomic Sequencing Classifier and Xpression Atlas to avoid unnecessary thyroid surgeries, Decipher Prostate Biopsy and Radical Prostatectomy tests for prostate cancer management, and the Prosigna Breast Cancer Assay. For lung conditions, it provides the Percepta Genomic Sequencing Classifier, Percepta Nasal Swab Test, and Envisia Genomic Classifier. It also offers the Immunoscore Colon Cancer test and collaborates with partners like Johnson & Johnson, Acerta Pharma, and CareDx.

Veracyte expanded annual revenue from $219.5M in FY2021 to $517.1M in FY2025, delivering a 5-year revenue CAGR of 34.5% from FY2020 to FY2025. Gross margin rose from 66.1% in FY2021 to 69.6% in FY2025. After net losses of -$75.6M in FY2021 and -$74.4M in FY2023, the business turned profitable with net income of $24.1M in FY2024 and $66.4M in FY2025, when operating margin reached 14.3%. Operating cash flow improved to $136.3M in FY2025, generating $126.6M in free cash flow. In the latest quarter ended June 30, 2026, revenue increased 15.5% year-over-year, while quarterly earnings grew 288.9%.

As of June 30, 2026, Veracyte held $485.2M in cash and short-term investments against $40.1M in total debt, yielding net cash of $445.1M. Shareholders' equity stood at $1.39B against total assets of $1.49B. Liquidity is supported by a current ratio of 9.16 and a debt-to-equity ratio of 0.03. In FY2025, capital expenditures were $9.7M, while share count increased 15.7% over 5 years.

At a last close of $43.12, Veracyte carries a market cap of $3.47B and an enterprise value of $3.08B. The stock trades at a trailing P/E of 30.8x and forward P/E of 23.6x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value-to-EBITDA multiple of 22.5x also stands above the peer median of 12.0x, alongside a price-to-sales ratio of 6.2x versus 4.1x for peers. Over the past year, Veracyte returned 20.4%, outpacing the S&P 500 return of 16.8%, but its 5-year return fell 4.5% versus an 83.0% gain for the index.

Wall Street coverage consists of 9 Strong Buy, 2 Buy, 1 Hold, and 1 Strong Sell ratings. Analysts set a mean price target of $58.42, representing 35.5% upside over the last close of $43.12. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $1.91 on revenue of $593.7M. For the next fiscal year, 12 analysts anticipate revenue of $658.7M and EPS of $1.95. The company beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Veracyte, Inc. (VCYT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VCYT income statement, VCYT balance sheet, VCYT key metrics, VCYT analyst forecast, VCYT chart. See the VCYT stock overview for the latest quote and news.